Acumen Pharmaceuticals (ABOS)
(Delayed Data from NSDQ)
$2.58 USD
+0.14 (5.74%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $2.58 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ABOS 2.58 +0.14(5.74%)
Will ABOS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ABOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABOS
Why Acumen Pharmaceuticals (ABOS) Stock Might be a Great Pick
Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?
ABOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year?
Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year?
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
Other News for ABOS
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
Buy Rating Justified by Acumen Pharmaceuticals’ Innovative Alzheimer’s Drug and Promising Clinical Trials
Buy Rating for Acumen Pharmaceuticals Backed by Promising Alzheimer’s Treatment Advances and Strong Financials
Acumen Pharmaceuticals Inc (ABOS) Q2 2024 Earnings Call Transcript Highlights: Robust Cash ...
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q2 2024